- Conditions
- B-Cell Lymphoma
- Interventions
- PS-341, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Filgrastim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 520
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
- Conditions
- Prediabetic State
- Interventions
- Oral glucose tolerance test
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Nontuberculous Mycobacterial Infections
- Interventions
- Rifabutin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at Tyler
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1984 – 2017
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
- Interventions
- Not listed
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Ovarian Cancer
- Interventions
- SC-003, SC-003 in combination with ABBV-181
- Drug
- Lead sponsor
- Stemcentrx
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Fayetteville, Arkansas • Duarte, California • Chicago, Illinois + 12 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- cisplatin, paclitaxel, phenoxodiol
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Focal Epilepsy, Temporal Lobe Epilepsy, Medically Refractory Epilepsy, Memory Disorders, Epilepsy Comorbidities, Epilepsy Intractable, Epilepsy Surgery, Epilepsy, Temporal Lobe, Memory Deficits, Memory Disorder, Spatial, Memory Dysfunction, Spatial Perception
- Interventions
- Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I)
- Behavioral · Device · Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Sacramento, California • Atlanta, Georgia
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Duarte, California • Fresno, California + 29 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1951, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services, Patient Participation, Health Behavior, Aging, Cardiovascular Diseases, Metabolic Syndrome, Cognitive Dysfunction, Frailty, Activities of Daily Living, Health Related Quality of Life, Health Equity, Telemedicine
- Interventions
- AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation
- Behavioral
- Lead sponsor
- William Brandenburg, MD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2099
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
- Interventions
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Biological · Drug
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Bacterial Infections
- Interventions
- Zyvox® / Linezolid
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer
- Interventions
- Alobresib, Enzalutamide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Urinary Tract Infections, Recurrent UTI, Antibiotic Resistant Infection
- Interventions
- Bifidobacterium infantis, Placebo, Antibiotics
- Dietary Supplement · Other · Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Jefferson, Louisiana
- Conditions
- Depressive Disorder, Major
- Interventions
- Navigated Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Magstim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Dunwoody, Georgia
- Conditions
- Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
- Interventions
- 3T Magnetic Resonance Imaging, Intracranial electroencephalography recordings, 7T Magnetic Resonance Imaging
- Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
- Interventions
- VERU-111, Enzalutamide, Abiraterone
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
- Conditions
- Refractory Epilepsy
- Interventions
- Electrical Stimulation
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- Fatty Liver
- Interventions
- fenofibrate, pioglitazone, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington